Safinamide

Limits on what this shows

• Why no grade: Two drug-specific animal studies were located, neither usable as nutrient-status evidence. Sepehr A, Taheri F, Heidarian S, Motaghinejad M, Safari S. Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: hypothetic possible role of BDNF/TrkB/PGC-1alpha signaling pathway and mitochondrial uncoupling protein-2 (UCP-2). 2020 (PMID 32682215). Wasan H, Singh D, Joshi B, Sharma U, Dinda AK, Reeta KH. Post stroke safinamide treatment attenuates neurological damage by modulating autophagy and apoptosis in experimental model of stroke in rats. Mol Neurobiol. 2021 (PMID 34453687, DOI 10.1007/s12035-021-02523-6). By their own titles, both studies investigate safinamide's purported neuroprotective, mitochondria-preserving pharmacology as a candidate treatment in a toxicity or stroke model, the same category of claim this project's framing rule excludes from nutrient-status grading as the drug's own intended/purported therapeutic mechanism (parallel to Hard Rule 2), so both are disclosed here but not used to grade a protective or a depletion finding either way. A revision pass specifically re-searched PubMed, Crossref, and OpenAlex for mitochondrial-burden evidence distinguishable from this purported-mechanism literature (an actual measured depletion or excess finding rather than more neuroprotection pharmacology) and found none; this confirms rather than merely repeats the original gap. No other safinamide-specific mitochondrial-burden evidence, in either direction, was found. Channels tried across the original review and this revision: PubMed search-listing pages (multiple phrasings across both passes; several successful listings, including one that newly surfaced the Wasan 2021 title, with individual PubMed abstract pages intermittently returning a bot-verification challenge rather than full-text content); Crossref works-search API (clean results, no genuine new safinamide mitochondrial-burden hit beyond the two studies above, confirmed via a bibliographic DOI lookup for the arthritis-model paper discussed under Oxidative stress); Europe PMC REST API (HTTP 429 rate-limited on every attempt in this revision pass, as in the original); Semantic Scholar Graph API (HTTP 429 on every attempt in both passes); OpenAlex works-search endpoint (HTTP 429 on search queries in this revision pass, though single-record DOI/PMID lookups on OpenAlex succeeded and were used to confirm the Wasan and arthritis-model abstracts); DailyMed/FDA label (no mitochondrial findings reported in Adverse Reactions, Clinical Pharmacology, or Nonclinical Toxicology beyond the retinal and reproductive findings noted in Monitoring). No circulating consumer claim regarding safinamide and mitochondrial function could be confirmed: the one general consumer drug-reference page checked (drugs.com, Xadago) carried no such claim, but a full consumer-web sweep remains limited because the WebSearch tool's budget was exhausted in both the original session and this revision, so the claim-audit side of this entry is partly tooling-limited rather than a fully confirmed zero.

Limits on what this shows

• Why no grade: Two drug-specific studies were located, neither usable as nutrient-status evidence. Gu X, Zhang G, Qin Z, Yin M, Chen W, Zhang Y, Liu X. Safinamide protects against amyloid beta (Abeta)-induced oxidative stress and cellular senescence in M17 neuronal cells. 2022 (PMID 35001806), an in vitro model of safinamide's purported antioxidant/neuroprotective pharmacology against amyloid-beta toxicity. Venegas FC, Sanchez-Rodriguez R, Luisetto R, Angioni R, Viola A, Canton M. Oxidative stress by the mitochondrial monoamine oxidase B mediates calcium pyrophosphate crystal-induced arthritis. Arthritis Rheumatol. 2023 (PMID 37695218, DOI 10.1002/art.42697), a murine model in which safinamide and rasagiline were dosed directly and both suppressed MAO-B-derived reactive-oxygen-species production and NLRP3 inflammasome activation, reducing joint inflammation. This project's framing rule treats both as the drug's own purported therapeutic mechanism (antioxidant/anti-inflammatory pharmacology under investigation for a candidate indication) rather than evidence about the patient's own nutrient or redox status, so both are disclosed but excluded from grading in either direction, matching the explicit caution that safinamide's antioxidant effects are intended pharmacology, not depletion evidence, and must not be conflated with it. A revision pass specifically searched for oxidative-stress evidence distinguishable from this purported-mechanism literature, which is what surfaced the Venegas 2023 study; because it is itself a demonstration of the drug's antioxidant mechanism of action (just in a non-Parkinson's disease model), it does not qualify as the kind of measured depletion/excess finding that would clear a grade, so the category remains ungraded even with this new source identified. The individual PubMed abstract page for the Gu 2022 record returned a bot-verification challenge rather than full text during both the original review and this revision, so only the title, authors, year, and PMID from the search-listing page were confirmed for that record; the Venegas 2023 abstract was confirmed in full via an OpenAlex DOI lookup after the Wiley publisher page returned an HTTP 403 and Europe PMC and PubMed's individual-record pages were both rate-limited or bot-challenged. No independent safinamide-specific evidence of drug-caused oxidative stress (the depletion direction) was found. Channels tried across both passes: PubMed search listings (multiple phrasings, several successful, including the listing that surfaced both titles above), Crossref works-search API (clean both times, no genuine new safinamide-oxidative-stress hit beyond the two studies above, and used for the successful DOI lookup on the Venegas paper), Europe PMC REST API (429 on every attempt in this revision pass), Semantic Scholar (429 on every attempt in both passes), OpenAlex (works-search endpoint 429 in this revision pass; single-record DOI lookup succeeded and supplied the Venegas abstract). DailyMed label reports no oxidative-stress marker or related laboratory abnormality beyond the ALT/AST shifts noted in Monitoring.

Limits on what this shows

• Why no grade: A PubMed search-listing query for "safinamide copper" returned a clean, explicit zero-result page ("No results were found," result count 0) in the original review. Crossref's works-search API, queried with copper- and ferritin-adjacent terms, returned no genuine safinamide-copper hit in either the original review or this revision pass (results were entirely unrelated ferritin or ceruloplasmin biochemistry papers with no safinamide connection). This revision pass re-attempted a combined PubMed query ("safinamide AND (copper OR iron OR ferritin OR ceruloplasmin)"), a fresh Crossref query ("safinamide copper ceruloplasmin"), and an OpenAlex works-search query for "safinamide copper"; all three were refused with HTTP 429 or, for PubMed, a bot-verification challenge page, before returning content. Europe PMC and Semantic Scholar queries for this term were also refused with HTTP 429 in this revision pass. This is disclosed as a persistent tooling limit on top of, not instead of, the clean PubMed and Crossref zero-results already obtained in the original review, which stand as a genuine, if now only partially re-confirmable, null finding. Mechanistically, MAO-B is a flavin(FAD)-dependent enzyme, not a copper-dependent one (copper-containing amine oxidases are a separate enzyme family), so there is no obvious cofactor-level reason to expect a safinamide-copper interaction, which is consistent with the absence of literature rather than a reason to skip the search. No circulating consumer claim regarding safinamide and copper could be confirmed, subject to the same consumer-web tooling limit noted under Mitochondrial burden.

Limits on what this shows

• Why no grade: A PubMed search-listing query for "safinamide iron" could not be completed to a clean result in the original review: an initial attempt was rate-limited (HTTP 429) and a retry returned a bot-verification challenge page rather than search content. This revision pass retried the same query and a combined query ("safinamide AND (copper OR iron OR ferritin OR ceruloplasmin)"); both again returned a bot-verification challenge page rather than content, so PubMed has not yielded a clean result for this term in either pass. Crossref's works-search API returned a clean result set for iron/ferritin terms with no genuine safinamide connection in any hit in the original review (all results were unrelated ferritin-biochemistry papers); a fresh Crossref attempt in this revision pass ("safinamide iron chelation") was refused with HTTP 429 before returning content. Europe PMC, Semantic Scholar, and OpenAlex works-search queries for this term were refused with HTTP 429 in both passes. Separately, and independent of the tooling gap above, this project's sibling dossiers for rasagiline and selegiline (both MAO-B inhibitors) document a real, drug-specific iron-chelation research program built around their shared propargylamine chemical scaffold (for example, hybrid iron-chelator/MAO-inhibitor compounds derived from the rasagiline and selegiline molecules). Safinamide does not share that scaffold: it is a benzylamino, non-propargylamine MAO-B inhibitor with an additional sodium-channel-blocking action, and no iron-chelating moiety is described for it in any source reviewed here. Extending the propargylamine-specific iron-chelation literature to safinamide would fail the cohort test (Hard Rule 6) on chemical grounds, so it is not attempted; this chemistry-based exclusion is a substantive finding, not a tooling artifact, and holds regardless of search-channel access. Parkinson's disease's own disease-intrinsic brain iron accumulation is a separate, well-documented phenomenon not attributed to safinamide here (Hard Rule 2). No circulating consumer claim regarding safinamide and iron could be confirmed, subject to the same consumer-web tooling limit noted under Mitochondrial burden.

Limits on what this shows

• Key negative/null findings: The source study measured colonic transit time and tissue dopamine content, not microbial composition, diversity, or any direct microbiome marker. Slowed transit is associated with compositional shifts in the general gastrointestinal-physiology literature, but that link was not tested for either rasagiline or safinamide directly.
• At-risk subgroups: None established for safinamide specifically. Patients already prone to Parkinson's disease-related constipation (a well-documented disease-intrinsic feature, not attributed to safinamide here) would be the plausible subgroup if the mechanism holds.
• Counter-evidence on record: None located specifically for safinamide. No safinamide-specific gut microbiome or motility study of any direction was found across PubMed, Europe PMC, Crossref, Semantic Scholar, or OpenAlex queries attempted in this review.

Regulatory status

Not addressed in the XADAGO label. Constipation is not listed as a labeled adverse reaction distinct from the general Parkinson's disease and dopaminergic-overlap profile.

Population evidence

Class extrapolation, Tier C for safinamide. The supporting study is drug-specific for rasagiline, not safinamide: Liu C, Zhang XL, Zhou L, et al. Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. Neurogastroenterol Motil. 2018 (rat model). Rasagiline was confirmed in the studied cohort; safinamide was not.

Mechanism

Named, shared at the class level: MAO-B inhibition raises local dopamine, and dopamine D1-receptor activation in the colon slows motility. Safinamide shares the MAO-B-inhibition component of this mechanism. Cohort-test caution: safinamide's MAO-B inhibition is reversible (rasagiline's is irreversible), and safinamide additionally blocks sodium channels and modulates glutamate release, actions rasagiline does not have, so the extrapolation is narrowed to the shared MAO-B pathway only and is not extended to any sodium-channel-mediated GI effect, which has no supporting literature at any tier.

Counter-evidence held on record

This is a narrow, explicitly labeled class extrapolation from a different MAO-B inhibitor (rasagiline), not a safinamide-specific finding, and it concerns motility, not microbial composition or diversity. It should never be presented to a consumer as "safinamide disrupts the gut microbiome." No supplement, probiotic, or dietary change is recommended on this basis.

Limits on what this shows

• Why no grade: The XADAGO label's trial-derived adverse-reaction table (N=223 at 50 mg, N=498 at 100 mg, N=497 placebo, pivotal 24-week trials) and its laboratory-abnormality summary report no hemoglobin, hematocrit, anemia, or red-cell finding of any kind; this is a genuine null/counter-evidence result from a reasonably sized Tier A source, not merely an unsearched question, and is recorded here as such. A PubMed search-listing query for "safinamide hemoglobin anemia" was rate-limited (HTTP 429) before returning content in the original review, and a fresh PubMed attempt for "safinamide hemoglobin" in this revision pass returned a bot-verification challenge page rather than content. A Crossref works-search query combining iron/hemoglobin/ATP terms returned no genuine safinamide hit in the original review; this revision pass re-ran a fresh, differently worded Crossref query ("safinamide hemoglobin anemia") and obtained a clean, completed result set of seven hits, none connected to safinamide (all were unrelated hemoglobinopathy and sickle-cell-anemia papers), which is an additional genuine null result from a channel that actually returned content this time, not merely another block. Europe PMC, Semantic Scholar, and OpenAlex works-search queries for this term were refused with HTTP 429 in both passes. No circulating consumer claim regarding safinamide and oxygen delivery, red blood cells, or anemia could be confirmed, subject to the same consumer-web tooling limit noted under Mitochondrial burden.

Limits on what this shows

• Why no grade: The same two drug-specific animal studies cited under Mitochondrial burden (Sepehr et al. 2020, PMID 32682215, mitochondrial uncoupling protein-2 and PGC-1alpha signaling in a methamphetamine-toxicity model; Wasan et al. 2021, PMID 34453687, autophagy and apoptosis modulation in a post-stroke rat model) are the only safinamide-specific sources touching cellular energy metabolism located across the original review and this revision pass; see the Overlap map for these shared sources. By their own framing both describe safinamide's purported protective pharmacology under investigation in a disease model, not a patient-facing ATP-production or energy-deficit finding, so per this project's framing rule both are disclosed but not used to grade a protective or a depletion finding in this category either. This revision pass specifically searched for ATP-production evidence distinguishable from that purported-mechanism literature and found none beyond the newly surfaced Wasan 2021 study, which falls in the same excluded category. Channels tried across both passes: PubMed search listings (multiple phrasings, with the revision pass's listing newly surfacing the Wasan title), Crossref works-search API (clean both times, no genuine hit beyond the two studies above), Europe PMC REST API (429 in both passes), Semantic Scholar (429 in both passes), OpenAlex (works-search endpoint 429 in the revision pass; single-record PMID lookup succeeded and supplied the Wasan abstract summary). No circulating consumer claim regarding safinamide and ATP, cellular energy, or fatigue could be confirmed, subject to the same consumer-web tooling limit noted under Mitochondrial burden.